Log in
ETR:MOR

MorphoSys AG (MOR.F) Stock Forecast, Price & News

€88.08
-1.06 (-1.19 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
€86.96
Now: €88.08
€89.32
50-Day Range
€89.14
MA: €103.87
€116.15
52-Week Range
€65.25
Now: €88.08
€146.30
Volume173,807 shs
Average Volume153,687 shs
Market Capitalization$2.88 billion
P/E Ratio26.83
Dividend YieldN/A
BetaN/A
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma. Its product pipeline includes MOR208, an antibody for the treatment of haematological cancers; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; MOR106, an antibody for rheumatoid arthritis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; and a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys' investigational compound tafasitamab (MOR208). The company was founded in 1992 and is headquartered in Planegg, Germany.
Read More
MorphoSys AG (MOR.F) logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.52 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+49-89-899270
Employees572

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$293.21 million
Cash Flow€24.05 per share
Book Value€20.07 per share

Profitability

Miscellaneous

Market Cap$2.88 billion
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
€88.08
-1.06 (-1.19 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MOR News and Ratings via Email

Sign-up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











MorphoSys AG (MOR.F) (ETR:MOR) Frequently Asked Questions

How has MorphoSys AG (MOR.F)'s stock been impacted by Coronavirus (COVID-19)?

MorphoSys AG (MOR.F)'s stock was trading at €91.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MOR stock has decreased by 3.3% and is now trading at €88.08.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of MorphoSys AG (MOR.F)?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys AG (MOR.F) in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for MorphoSys AG (MOR.F)
.

When is MorphoSys AG (MOR.F)'s next earnings date?

MorphoSys AG (MOR.F) is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for MorphoSys AG (MOR.F)
.

What price target have analysts set for MOR?

8 analysts have issued 1-year price objectives for MorphoSys AG (MOR.F)'s shares. Their forecasts range from €110.00 to €140.00. On average, they expect MorphoSys AG (MOR.F)'s stock price to reach €122.50 in the next year. This suggests a possible upside of 39.1% from the stock's current price.
View analysts' price targets for MorphoSys AG (MOR.F)
.

Who are some of MorphoSys AG (MOR.F)'s key competitors?

What other stocks do shareholders of MorphoSys AG (MOR.F) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MorphoSys AG (MOR.F) investors own include Novo Nordisk A/S (NVO), Gilead Sciences (GILD), Solaredge Technologies (SEDG), Supernus Pharmaceuticals (SUPN), AbbVie (ABBV), Abbott Laboratories (ABT), Mercadolibre (MELI), Neurocrine Biosciences (NBIX), Nightstar Therapeutics (NITE) and NVIDIA (NVDA).

Who are MorphoSys AG (MOR.F)'s key executives?

MorphoSys AG (MOR.F)'s management team includes the following people:
  • Dr. Jean-Paul Kress, Chairman of Management Board, MD & CEO (Age 55, Pay $2.03M)
  • Mr. Jens H. Holstein, CFO & Member of the Management Board (Age 57, Pay $1.43M)
  • Dr. Malte Peters M.D., Chief R&D Officer and Member of the Management Board (Age 58, Pay $1.37M)
  • Mr. Roland Wandeler Ph.D., COO & Member of Management Board (Age 48)
  • Mr. Klaus De Wall, Head of Accounting & Tax
  • Ms. Lara Smith Weber, Head of Controlling, Corp. Fin. & Corp. Devel.
  • Dr. Margit Urban, Head of Discovery Alliances & Technologies
  • Dr. Sarah Fakih, VP & Head of Corp. Communications and Investor Relations
  • Dr. Armin Weidmann, Head of Compliance and Quality Assurance
  • Ms. Charlotte Lohmann, Sr. VP & Gen. Counsel (Age 50)

What is MorphoSys AG (MOR.F)'s stock symbol?

MorphoSys AG (MOR.F) trades on the ETR under the ticker symbol "MOR."

What is MorphoSys AG (MOR.F)'s stock price today?

One share of MOR stock can currently be purchased for approximately €88.08.

How big of a company is MorphoSys AG (MOR.F)?

MorphoSys AG (MOR.F) has a market capitalization of $2.88 billion and generates $293.21 million in revenue each year. MorphoSys AG (MOR.F) employs 572 workers across the globe.

What is MorphoSys AG (MOR.F)'s official website?

The official website for MorphoSys AG (MOR.F) is www.morphosys.de.

How can I contact MorphoSys AG (MOR.F)?

MorphoSys AG (MOR.F)'s mailing address is Semmelweisstr. 7, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-899270.

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.